US Pre-Market SEC Filings Roundup — June 04, 2026

04-06-2026

WISeKey and its subsidiary WISeSat.Space Corp. announced the confidential submission of an amended draft registration statement on Form F-4 with the SEC on May 29, 2026, in connection with their proposed business combination with Columbus Acquisition Corp (CAC), a SPAC. The combined company is expected to trade on Nasdaq under the ticker symbol "WSAT." However, the transaction remains subject to several closing conditions, including SEC effectiveness, CAC shareholder approval, and Nasdaq listing approval, and there is no guarantee that the business combination will be completed in a timely manner or at all.

• · The amended draft registration statement was confidentially submitted to the SEC on May 29, 2026.
• · The Business Combination Agreement was originally dated November 9, 2025.
• · WISeSat is a British Virgin Islands business company operating through its wholly owned subsidiary WISeSat.Space AG.
• · CAC is led by Fen 'Eric' Zhang (Chairman and CEO) and Jie 'Janet' Hu (CFO).
• · Maxim Group LLC is acting as exclusive financial advisor to WISeKey; Ellenoff Grossman & Schole LLP is legal advisor to WISeSat and Pubco; Loeb & Loeb LLP is legal advisor to CAC.
• · WISeKey has deployed over 1.6 billion microchips across various IoT sectors.

04-06-2026

X-Energy, Inc. reported a net loss of $166.2M for Q1 2026, a significant increase from a $10.2M loss in Q1 2025, driven by a $108.9M mark-to-market loss on warrant liabilities. Total revenues and grant income more than doubled to $43.4M from $20.8M, primarily due to a 133.5% surge in services revenue to $39.9M. However, operating expenses also more than doubled to $109.5M, and cash and cash equivalents fell sharply from $458.9M to $224.1M.

• · Accounts receivable from DOE decreased from $23.6M at Dec 31, 2025 to $20.0M at Mar 31, 2026.
• · Unbilled receivables and contract assets from DOE increased from $39.6M to $51.1M.
• · Capital expenditures increased significantly to $43.0M in Q1 2026 from $11.2M in Q1 2025, partially offset by $28.8M in government grant reimbursements.
• · The company issued 19,576,222 Series C-1 Preferred Units upon conversion of the 2024 Warrant, increasing mezzanine equity by $365.2M.
• · Unit-based compensation expense rose to $4.3M in Q1 2026 from $65K in Q1 2025.
• · Total assets remained relatively flat at $1.20B vs $1.21B at year-end 2025.
• · The company's accumulated deficit grew to $1.40B from $1.24B at Dec 31, 2025.

04-06-2026

TETRA Technologies priced an underwritten public offering of 10,810,811 shares of common stock at $9.25 per share on June 2, 2026, expecting net proceeds of approximately $94.0 million. The underwriters fully exercised their 30-day over-allotment option on June 3, 2026 for an additional 1,621,621 shares, adding approximately $15.0 million in gross proceeds. The company intends to use the net proceeds for general corporate purposes, including construction of its Arkansas bromine project.

• · Offering was made under a Form S-3 registration statement (File No. 333-287210) filed May 12, 2025 and declared effective May 22, 2025.
• · Underwriting agreement includes a 60-day lock-up period for the company without written consent from J.P. Morgan Securities LLC.
• · The Underwriting Agreement contains customary representations, warranties, indemnification, and termination provisions.
• · The legal opinion on the validity of the issuance and sale was provided by Vinson & Elkins L.L.P.

04-06-2026

TruBridge, Inc. (TBRG) is being acquired by IKS in an all-cash merger valued at $26.25 per share, representing an 87.5% premium over the unaffected $14.00 closing price on March 30, 2026. The Board unanimously recommends stockholders vote 'FOR' the merger and related executive compensation proposals at a Special Meeting scheduled for July 7, 2026. However, the merger is taxable for U.S. holders, and failure to vote will effectively count as a vote 'AGAINST' the merger proposal.

• · Special Meeting will be held virtually on July 7, 2026 at 8:00 a.m. Central Time.
• · Stockholders of record as of the Record Date must vote; failure to vote has the same effect as a vote 'AGAINST' the merger.
• · The Named Executive Officer Merger-Related Compensation Proposal is non-binding and advisory only; its approval is not required to consummate the merger.
• · Broker non-votes will not be counted for quorum and will have the same effect as a vote 'AGAINST' the merger proposal.
• · Innisfree will be paid a base fee of $20,000 plus a contingent success fee of $10,000 for proxy solicitation.

04-06-2026

NextTrip, Inc. (NTRP) borrowed $200,000 on May 29, 2026 from The Donald P. Monaco Insurance Trust, a related party (director Donald P. Monaco is trustee), as part of a series of short-term unsecured loans. The total principal balance of these Monaco Loans is now $500,000, accruing interest at 7.5% simple interest per annum, with a maturity date of June 30, 2026. The loans were approved by the Board of Directors and Audit Committee, but the short-term nature and reliance on insider funding may signal liquidity constraints.

• · The Monaco Loans commenced on March 25, 2026, and the $200,000 borrowed on May 29 is the latest in that series.
• · The loans are unsecured and mature on June 30, 2026, indicating very short-term financing.
• · The loans were approved by both the Board of Directors and the Audit Committee, suggesting governance oversight of the related-party transaction.

04-06-2026

Watu Metals Acquisition Corp filed an S-1 registration statement for an IPO of 10,000,000 units at $10.00 per unit, with an over-allotment option of up to 1,500,000 units. The sponsor will purchase 230,000 private units (up to 246,500 if over-allotment is exercised) for $2,300,000. Net proceeds of $100,500,000 (or $115,575,000 if over-allotment exercised) will be held in trust, representing $10.05 per public unit. The company has 12 months from the effective date to complete a business combination or will redeem public shares.

• · The sponsor purchased initial shares at approximately $0.009 per share.
• · Each public right entitles the holder to receive one-eighth (1/8) of one ordinary share upon consummation of a business combination.
• · Rights will expire worthless if no business combination is completed within 12 months.
• · Initial shares are subject to a lock-up: 50% until six months after business combination or when share price reaches $11.50 for 20 trading days within 30, and the remaining 50% for six months after business combination.
• · Private units are locked up for 30 days following business combination.
• · Representative shares are locked up for 180 days from commencement of sales per FINRA Rule 5110(e)(1).
• · The company must complete a business combination within 12 months from the effective date of the registration statement or redeem public shares.

04-06-2026

Genco Shipping & Trading Limited (GNK) issued a letter to shareholders opposing Diana Shipping's inadequate $24.80 per share tender offer and proxy fight to replace Genco's board. Genco highlights its Comprehensive Value Strategy, which has delivered $7.16 per share in dividends over 27 consecutive quarters, and notes that Diana's offer is below the mean analyst NAV estimate of $26.66 and median of $27.10. Genco recommends shareholders not tender shares and vote for its nominees, while warning that Diana's nominees have ties to bankruptcy and value destruction.

• · Genco's annual meeting is scheduled for June 18, 2026.
• · Diana's offer is below liquidation value and lacks a control premium.
• · Genco's board is majority independent and highly qualified.
• · Diana's CEO may personally benefit from a potential acquisition via sale and purchase fees to an affiliated entity.
• · Diana's nominees include individuals with ties to bankruptcy (Sterling Shipping, Bulk Invest) and shareholder value destruction (Statt Torsk).
• · Genco is ranked in the industry's top quartile for corporate governance, while Diana is in the third quartile.

04-06-2026

CrowdStrike reported a net income of $27.8M for Q1 FY26, a significant turnaround from a net loss of $104.3M in Q1 FY25. Total revenue grew 25.6% YoY to $1.39B, driven by subscription revenue growth of 25.7%. However, the company generated negative operating cash flow from changes in deferred revenue, which declined $36.7M, and cash and cash equivalents fell 12.9% from January 2026 to $4.55B, partly due to $881.4M in acquisition spending and $175.6M in share repurchases.

• · Subscription gross margin improved to 78.2% in Q1 FY26 from 77.0% in Q1 FY25.
• · Professional services gross margin declined to 16.9% in Q1 FY26 from 11.7% in Q1 FY25.
• · Stock-based compensation expense was $297.7M in Q1 FY26, up from $247.7M in Q1 FY25.
• · The company repurchased 480,000 shares for $175.6M during Q1 FY26.
• · Goodwill increased 66.3% to $2.27B due to acquisitions.
• · Deferred revenue (current) declined 1.5% sequentially to $3.37B.
• · Cash used in investing activities was $994.1M, primarily for acquisitions.
• · Net cash provided by operating activities increased 53.8% YoY to $590.9M.

04-06-2026

BlackRock Private Investments Fund and BlackRock HPS Credit Strategies Fund are holding a joint special meeting of shareholders on July 22, 2026 to elect seven Board Nominees to each Fund's Board of Trustees. The election is required because less than a majority of current Board Members were elected by shareholders following a recent retirement. The Boards unanimously recommend voting 'FOR' all nominees.

• · Meeting will be held virtually on July 22, 2026 at 11:00 a.m. Eastern time.
• · Record Date for shareholders is May 26, 2026.
• · Shareholders can vote by telephone, Internet, mail, or at the virtual meeting.
• · Beneficial shareholders must register in advance to vote at the meeting by submitting proof of proxy power to shareholdermeetings@computershare.com.
• · Two of the seven nominees are current Board Members who were appointed but not yet elected by shareholders.
• · The other five nominees are proposed to align each Fund's Board composition with the BlackRock Fixed-Income Complex.
• · The meeting is required under the 1940 Act because less than a majority of current Board Members were elected by shareholders.
• · Computershare Fund Services is acting as proxy solicitor (toll-free: 877-811-6280).

04-06-2026

Interactive Strength, Inc. (TRNR) announced a change of date for its 2026 Annual Meeting of Stockholders from June 4 to June 8, 2026, due to changes in planned travel for key participants. The record date of April 8, 2026, remains unchanged. The filing is a definitive additional proxy statement (DEFA14A) and does not contain any financial results or performance metrics.

• · The Annual Meeting was originally scheduled for June 4, 2026, and has been rescheduled to June 8, 2026 at 10:00 a.m. Central Time.
• · The record date for the Annual Meeting remains April 8, 2026.
• · Only stockholders of record as of the close of business on the record date are entitled to vote at the postponed meeting.
• · The company's brands include Wattbike, CLMBR, FORME, and Ergatta, which combine hardware, smart technology, and immersive content.

04-06-2026

RadNet, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, where all four proposals were approved. Stockholders elected six directors, ratified Ernst & Young LLP as the independent auditor, approved executive compensation on a non-binding advisory basis, and approved an amendment and restatement of the Equity Incentive Plan. The meeting had strong shareholder turnout with 93.58% of eligible shares represented.

• · Proposal 1 (Director Election): All six directors were elected. Laura P. Jacobs received the lowest 'For' votes (56,930,064) and the highest 'Withheld' votes (8,203,142) among the nominees.
• · Proposal 2 (Ratification of Auditor): Ratification of Ernst & Young LLP passed with 72,890,772 'For' votes, 346,990 'Against', and 14,745 abstentions.
• · Proposal 3 (Advisory Vote on Executive Compensation): Approved with 61,158,497 'For', 3,892,047 'Against', and 82,662 abstentions.
• · Proposal 4 (Equity Incentive Plan Amendment): Approved with 63,254,838 'For', 1,844,622 'Against', and 33,746 abstentions.
• · Broker non-votes totaled 8,119,301 on Proposals 1, 3, and 4.

04-06-2026

Taylor Morrison Home Corporation filed a DEFA14A (additional proxy material) relating to its proposed acquisition by Berkshire Hathaway Inc. The filing serves as a notice to shareholders that a definitive proxy statement will be filed and urges investors to read it carefully. No financial terms, transaction value, or specific timeline were disclosed in this communication.

• · The filing is a DEFA14A (additional proxy material) filed on June 4, 2026.
• · The proposed acquisition is by Berkshire Hathaway Inc.
• · Taylor Morrison will file one or more proxy statements with the SEC in connection with the transaction.
• · Participants in the solicitation include directors and executive officers of Taylor Morrison; details are in the 2026 annual meeting proxy statement filed April 10, 2026.
• · Shareholders can obtain free copies of documents via SEC website or Taylor Morrison's investor relations page.

04-06-2026

This is a DEFA14A (additional definitive proxy soliciting material) filing by Kennedy-Wilson Holdings, Inc., submitted on June 4, 2026. The filing incorporates by reference the company’s Annual Report for the year ended December 31, 2025, and other SEC filings including subsequent Form 10-Q and Form 8-K reports.

• · Filing type is DEFA14A (additional definitive proxy materials).
• · Filing date is June 04, 2026.
• · Incorporates by reference the Form 10-K for the year ended December 31, 2025.
• · Also incorporates by reference subsequent Form 10-Q and Form 8-K filings.

04-06-2026

Janus Detroit Street Trust filed a DEFA14A soliciting material on June 4, 2026, regarding a Joint Special Meeting of Shareholders for Janus Henderson mutual funds/ETFs. The filing includes voicemail and automated phone scripts urging shareholders to vote before the meeting deadline, with a toll-free number (1-855-206-23XX) and extended hours for assistance. No financial data or performance metrics are disclosed in this filing.

• · Filing type is DEFA14A (definitive additional soliciting materials) under SEC Rule 14a-12.
• · Shareholder voting deadline is on an unspecified date in 2026.
• · Shareholders can vote by phone at 1-855-206-23XX, Monday–Friday 9:00 a.m.–10:00 p.m. ET, and weekends 10:00 a.m.–6:00 p.m. ET.
• · The filing includes both a generic voicemail script and an automated phone (PL) script for adjournment reminders.

04-06-2026

This DEFA14A filing contains soliciting material for a Joint Special Meeting of Shareholders of Janus Investment Fund, including voicemail and automated call scripts urging shareholders to vote their shares. The materials provide contact information and deadlines for voting, but no financial results or performance data are disclosed.

• · Shareholders can vote by calling 1-855-206-23XX, Monday through Friday 9:00 a.m. to 10:00 p.m. ET, and weekends 10:00 a.m. to 6:00 p.m. ET.
• · The filing includes both a generic voicemail script and an automated (PL) script for adjournment reminders.
• · No fee was required for this filing.

04-06-2026

America Great Health reported a net loss of $85,363 for the three months ended September 30, 2025, a significant improvement from a net loss of $146,967 in the same period last year. Revenue increased 33.8% to $187,559, driven by strong growth in the United States segment. However, the company remains deeply insolvent with a shareholders' deficit of $5,829,109 and total liabilities of $6,070,405, while cash declined 36.3% to $28,079.

• · Revenue from the United States segment surged 144.7% to $60,425 (32% of total) from $24,692 (17% of total) in Q3 FY24.
• · Asia segment revenue grew 7.2% to $127,134 from $118,647, but its share of total revenue fell from 83% to 68%.
• · Cost of goods sold increased 560.6% to $74,880 from $11,335, causing gross margin to contract from 91.9% to 60.1%.
• · Selling, general and administrative expenses decreased 41.9% to $116,063 from $199,650, primarily due to a 48.5% drop in general and administrative expense.
• · Interest expense rose 7.7% to $81,982 from $76,127, contributing to total other expenses of $81,979.
• · Net cash used in operating activities improved to a positive $44,466 from negative $95,578 in the prior year period.
• · Net cash used in financing activities was $60,524, compared to $88,371 provided in Q3 FY24.
• · Total current liabilities of $3,779,008 exceed total current assets of $185,048 by a ratio of 20.4:1, indicating severe liquidity risk.
• · Accumulated deficit deepened to $10,866,708 from $10,781,345 at June 30, 2025.
• · The company has no accounts receivable and a $9,000 inventory valuation reserve.

04-06-2026

AVITA Medical, Inc. held its 2026 Annual Meeting on June 3, 2026, where stockholders approved all 15 proposals, including the election of all seven director nominees, an increase in the non-executive director cash fee pool from $750,000 to $900,000 per annum, and the issuance of equity awards to directors and officers. However, several proposals received notable opposition, with votes against ranging from approximately 1.8 million to 2.7 million shares, and broker non-votes of 3.89 million shares on most items, indicating mixed shareholder sentiment on certain governance and compensation matters.

• · All seven director nominees were elected with votes for ranging from 10,700,424 to 11,176,792, and votes withheld from 525,113 to 1,001,481.
• · Ratification of Grant Thornton LLP as independent auditor passed with 14,962,654 votes for, 255,151 against, and 374,642 abstentions.
• · Proposal to increase director fee pool to $900,000 passed with 8,582,602 for, 2,710,656 against, and 408,647 abstentions (plus 3,890,542 broker non-votes).
• · Annual equity grants to each non-executive director (22,214 RSUs and 16,133 options) passed with votes for ranging from 8,722,810 to 8,869,562, and votes against from 2,411,009 to 2,544,450.
• · Initial grant to Dr. Michael Tarnoff (26,250 RSUs and 19,063 options) passed with 8,791,498 for, 2,433,367 against, and 477,040 abstentions.
• · Initial grant to Joseph Woody (40,547 RSUs and 29,446 options) passed with 8,863,312 for, 2,395,376 against, and 443,217 abstentions.
• · Advisory vote on executive compensation (Say-on-Pay) passed with 8,918,272 for, 2,202,213 against, and 581,420 abstentions.
• · Advisory vote on frequency of Say-on-Pay favored 1 year with 9,545,151 votes, versus 924,743 for 2 years, 650,252 for 3 years, and 581,759 abstentions.
• · Issuance of warrants to Perceptive (up to 650,000 shares, 10-year term) passed with 9,322,532 for, 1,769,627 against, and 609,746 abstentions.
• · Approval to issue additional 10% equity securities under ASX Rule 7.1A passed with 8,947,195 for, 2,223,106 against, and 531,604 abstentions.

04-06-2026

QXO, Inc. announced that its subsidiary QXO Building Products priced a $3.0B dual-tranche senior notes offering on June 3, 2026, consisting of $1,500.0M of 6.500% Senior Notes due 2031 and $1,500.0M of 6.875% Senior Notes due 2034, both at par. The offering is expected to close on June 17, 2026, subject to customary conditions. The filing also includes cautionary forward-looking statements regarding the proposed acquisition of TopBuild Corp., highlighting risks that the acquisition may not be completed on anticipated terms or at all.

• · The Notes are being offered to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
• · The offering is subject to market and other conditions, with closing expected June 17, 2026.
• · The filing includes risk factors related to the proposed TopBuild acquisition, including potential failure to obtain shareholder approvals, termination fees, and financing risks.
• · QXO's common stock trades on NYSE under symbol QXO; its depositary shares trade under QXO.PRB.

04-06-2026

Spring Valley Acquisition Corp. III (SVAC) filed a 425 communication regarding its proposed business combination with General Fusion Inc., a fusion energy developer. The transaction implies a pro-forma equity value of approximately $1 billion, including a $107.7 million PIPE and about $230 million from SVAC's trust capital. General Fusion, which has raised over $400 million to date, plans to use proceeds to advance its LM26 demonstration program and targets a first commercial plant by the mid-2030s, but has not yet built a commercial reactor producing net energy.

• · General Fusion was founded in 2002 and is one of the oldest privately funded fusion ventures.
• · The company's MTF approach uses a liquid-lithium liner to compress magnetized plasma, avoiding superconducting magnets and high-powered lasers.
• · LM26 milestones: heat plasma to 1 keV (10 million °C), then 10 keV (100 million °C), and ultimately reach the Lawson criterion for net fusion energy.
• · Spring Valley's earlier SPAC vehicles took NuScale Power and Eagle Nuclear Energy public, and brought Renewable Energy Group public at $10/share (later sold to Chevron for $61.50/share in ~$3B sale).
• · NuScale Power has $1B liquidity and a 6 GW deployment program with ENTRA1 Energy and TVA; its SMR design is NRC-approved.
• · Oklo's Aurora powerhouse received NRC approval for Principal Design Criteria, with commercial deployment at Idaho National Lab targeted for late 2027.
• · Centrus Energy raised full-year revenue guidance and has a $2.3B LEU backlog plus a $900M HALEU award.
• · NANO Nuclear submitted a Construction Permit Application to the NRC for its KRONOS MMR prototype at University of Illinois.
• · The combined company is expected to trade on Nasdaq under ticker 'GFUZ' after closing targeted for mid-2026.
• · General Fusion's leadership will participate in Stifel Boston Conference (June 2-3), ROTH London Conference (June 16-18), and FusionX:Americas (June 9-11).

04-06-2026

Angel Studios, Inc. disclosed in an 8-K filing that, effective May 29, 2026, it began publicly reporting its current active paying Angel Guild member count on its website. The metric is updated regularly, and investors are directed to the company's website for the most current data. No specific member count or financial figures were provided in the filing.

• · The disclosure is made under Item 7.01 (Regulation FD) and is not deemed filed for SEC liability purposes.
• · The company is an emerging growth company as defined under the Securities Act.
• · The company's Class A Common Stock trades on the NYSE under the symbol ANGX.
• · The filing was signed by CFO Scott Klossner on June 4, 2026.

04-06-2026

ROKIT America, Inc. filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 2,631,579 shares of common stock, with an estimated price range of $8.50 to $10.50 per share (midpoint $9.50). The company, an emerging growth and smaller reporting company, plans to list on Nasdaq under the symbol "RKAM" and expects gross proceeds of approximately $25.0 million (or $28.75 million with full over-allotment). The offering is underwritten by Maxim Group LLC, with a 6.5% underwriting discount and a 45-day over-allotment option for up to 394,737 additional shares. The company focuses on dietary supplements (NMN-based Reverse Aging Products) and an AI-driven Organ Regeneration Platform licensed from its parent, ROKIT Healthcare, but faces risks including no existing public market, reliance on a single parent company, and a highly competitive dietary supplement market with low barriers to entry.

• · The company was founded in 2019 and has focused on NMN-based dietary supplements.
• · The company's parent, ROKIT Healthcare, is a publicly traded company in South Korea and will remain a major stockholder after the offering.
• · The company has applied to list on Nasdaq under the symbol 'RKAM'.
• · The offering is contingent upon Nasdaq listing approval.
• · The company has elected to comply with reduced reporting requirements as an emerging growth company and smaller reporting company.
• · The dietary supplement market is highly competitive with low barriers to entry.
• · The company's ORP technology is licensed from ROKIT Healthcare under an Intellectual Property License Agreement dated August 27, 2025.
• · The company has a Support Agreement with ROKIT Healthcare for financial, legal, HR, sales, and marketing services.
• · The company has an Advisory Service Agreement with CKIUFC (controlled by CFO Ha Young Kim) for operational advisory and CFO services.
• · The underwriters will receive warrants to purchase 5% of the shares sold at 125% of the IPO price (not registered under this S-1).

04-06-2026

Denali Therapeutics Inc. held its annual meeting on June 3, 2026, with 86.96% of outstanding shares represented. All three Class III director nominees (Jennifer Cook, David Schenkein, and Ryan Watts) were elected, and stockholders ratified Ernst & Young as the independent auditor for FY2026. Additionally, the advisory vote on executive compensation was approved, though it received notable opposition with 7,088,810 votes against and 717,733 abstentions.

• · The advisory vote on executive compensation received 7,088,810 votes against and 717,733 abstentions, indicating notable shareholder dissent despite approval.
• · Jennifer Cook received the lowest support among director nominees with 75,998,259 votes for and 48,847,029 withheld.
• · Ratification of Ernst & Young as auditor passed overwhelmingly with 137,516,267 votes for and only 420,305 against.

04-06-2026

PagSeguro Digital Ltd. filed its 20-F/A annual report for FY2025, showing total revenue and income increased 8.5% YoY to R$20,410,512 (thousands) driven by strong growth in financial income (+26.6% YoY). Net income was essentially flat at R$2,118,362 thousand compared to R$2,116,368 thousand in FY2024. However, the core revenue from transaction activities and other services declined 11.2% YoY to R$8,158,654 thousand, while financial costs rose sharply by 39.6% to R$5,228,792 thousand, partially offsetting gains. Operating cash flow turned strongly positive at R$7,562,429 thousand after being negative in the prior year.

• · Total assets increased 2.1% from R$72,900,617 thousand to R$74,409,523 thousand
• · Total liabilities increased 2.6% from R$58,232,245 thousand to R$59,769,953 thousand
• · Equity decreased slightly by 0.2% from R$14,668,372 thousand to R$14,639,570 thousand
• · Accounts receivable (current) decreased slightly from R$56,167,315 thousand to R$55,563,067 thousand
• · Compulsory reserve decreased from R$4,761,404 thousand to R$4,271,581 thousand
• · Credit portfolio (current+non-current) increased from R$3,152,793 thousand to R$4,206,367 thousand
• · Banking issuances (current) increased sharply from R$12,677,098 thousand to R$18,947,864 thousand
• · Borrowings (current) decreased from R$4,521,503 thousand to R$2,436,846 thousand
• · Obligations to FIDC quota holders decreased from R$1,151,384 thousand (current+non-current) to R$1,171,463 thousand (all current)
• · Dividends of R$801,746 thousand were distributed in FY2025, a new line item not present in FY2024
• · Share capital remains at R$26 thousand; share cancellation of R$1,208,680 thousand was executed in FY2025
• · Other comprehensive income became more negative: from (R$82,913 thousand) to (R$207,878 thousand), driven mainly by losses on financial assets through OCI

04-06-2026

News Corp filed an 8-K on June 4, 2026, disclosing that it provided daily transaction information to the Australian Securities Exchange (ASX) regarding its stock repurchase program, which authorizes up to $1 billion in share repurchases. The filing includes forward-looking statements about the company's intent to repurchase shares from time to time.

• · The repurchase program covers both Class A common stock (NWSA) and Class B common stock (NWS).
• · Disclosure to ASX is required on a daily basis under ASX rules.
• · The company also discloses repurchase program information in quarterly and annual reports.

04-06-2026

Gentherm announced its acquisition of Modine's Performance Technologies business via a Reverse Morris Trust, creating a combined company with $2.6B revenue and $320M EBITDA on day one. The deal is expected to close in early Q4 2026. While the core automotive business is expected to grow mid-single digits, the company faces near-term integration risks and the Modine business is coming off a trough in commercial vehicle and off-highway markets.

• · Gentherm expects to double its Medical business to $100M by 2030.
• · The company is consolidating footprint in every region, to be completed by end of 2027.
• · Modine's Performance Technologies business is only 20% light vehicle; other markets include construction, agriculture, mining, commercial vehicle, and power generation.
• · Post-transaction leverage is expected to be just under 1 turn.
• · The transaction is structured as a Reverse Morris Trust with an equity component and distribution.
• · Gentherm realigned organization from regional to functional structure, removing layers of management at director level and above.

04-06-2026

Greenwich LifeSciences reported a net loss of $5.66M for Q1 2026, more than doubling from a $2.74M loss in Q1 2025, driven by a 129% surge in R&D expenses to $5.21M. The company raised $9.03M net through its ATM program, boosting cash to $10.51M from $6.18M at year-end 2025, but operating cash burn also widened to $4.70M from $1.83M. Stockholders' equity improved to $5.27M from $0.35M, though the accumulated deficit grew to $92.79M.

• · Revenue remained zero for both Q1 2026 and Q1 2025.
• · General and administrative expenses increased only 4.1% YoY to $0.52M.
• · Stock-based compensation was unchanged at $1.54M in both periods.
• · Accounts payable decreased 7.5% from $4.87M to $4.51M.
• · Unreimbursed expenses dropped 81.1% from $0.28M to $52,382.
• · Weighted average diluted shares outstanding rose 10.6% to 14.57M.
• · Net loss per share widened from $(0.21) to $(0.39).

04-06-2026

Silver Bow Mining Corp. issued a letter to shareholders on June 3, 2026, providing a business update on recent activities and its plan of operations. The filing is furnished under Item 7.01 (Regulation FD) and does not contain specific financial figures or performance metrics. No forward-looking guidance, quantitative data, or period-over-period comparisons were disclosed in the 8-K itself.

• · The 8-K was filed on June 4, 2026, reporting an event dated June 3, 2026.
• · Exhibit 99.1 (letter to shareholders) is furnished, not filed, under Item 7.01.
• · Silver Bow Mining Corp. is an emerging growth company and has not elected the extended transition period for new accounting standards.
• · The company is headquartered in Butte, Montana (1401 Idaho Street, 59701).
• · Common shares trade under ticker SBMT on NYSE American.
• · No financial results, projections, or material definitive agreements were disclosed in the 8-K.

04-06-2026

Waystar Holding Corp. held its 2026 Annual Meeting on June 1, 2026, with 180.9 million shares voted out of 191.7 million entitled. All four Class II director nominees were re-elected, KPMG LLP was ratified as independent auditor for FY2026, and stockholders selected a one-year frequency for future advisory votes on executive compensation. The company will hold such advisory votes annually until at least the 2032 annual meeting.

• · John Driscoll received the highest number of withheld votes among directors (23,913,512), representing about 13.5% of votes cast for his election.
• · The ratification of KPMG LLP was nearly unanimous with 180,884,990 votes for and only 7,071 against.
• · The one-year frequency for advisory votes on executive compensation received strong support (176,047,038 votes), with only 1,285,275 votes for three years and 4,742 for two years.
• · Broker non-votes totaled 3,488,788 for all director elections and the frequency vote, but were not applicable for the auditor ratification.

04-06-2026

Smith-Midland Corporation received a notice from Nasdaq on May 29, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, violating Nasdaq Listing Rule 5250(c)(1). The notice has no immediate effect on the listing of its common stock on the Nasdaq Capital Market, and the company is working to file the Form 10-Q as promptly as possible. If unable to file by July 28, 2026, the company intends to submit a plan to regain compliance.

• · The company has until July 28, 2026, to file the Form 10-Q or submit a compliance plan to Nasdaq.
• · A press release regarding the late filing was issued on June 3, 2026, and attached as Exhibit 99.1 to the 8-K.

04-06-2026

Atkore Inc. entered into a settlement agreement on June 3, 2026, with the End User Plaintiffs in the In re PVC Pipe Antitrust Litigation, agreeing to pay $50 million to resolve all claims. The settlement is subject to court approval and is expected to be funded from available cash, with no material adverse effect on liquidity or leverage metrics. The company does not admit fault and believes the settlement reduces legal uncertainty, but there is no assurance of final court approval.

• · The settlement will be reflected as a non-operating expense in the quarter ending June 26, 2026.
• · The settlement payment is due on or about 21 days after preliminary court approval.
• · The settlement covers all claims including potential parens patriae claims.
• · The company previously entered into settlement agreements with two of the three putative classes on April 28, 2026.
• · If the settlement is not approved, the company plans to vigorously defend itself.

04-06-2026

Activate Energy Acquisition Corp. appointed David Whitby as a director on May 20, 2026. Mr. Whitby is a retired oil and gas executive who formerly served as Managing Director of Nido Petroleum Ltd., growing it from a market capitalization of A$1 million to A$600 million. The appointment appears to be a standard board addition with no disclosed arrangements, family relationships, or material interests requiring disclosure.

• · Mr. Whitby holds a bachelor of engineering degree from the Royal Military College of Canada
• · There are no family relationships between Mr. Whitby and any other director or executive officer
• · The company is incorporated in the Cayman Islands and files under SEC file number 001-42992
• · The company qualifies as an emerging growth company and has elected not to use the extended transition period for complying with new or revised accounting standards

04-06-2026

BNY Mellon Strategic Municipal Bond Fund, Inc. filed additional definitive proxy soliciting materials on June 4, 2026, related to a shareholder meeting. The filing includes a graphic image but no specific financial data or material changes.

04-06-2026

BNY MELLON STRATEGIC MUNICIPALS, INC. filed a DEFA14A (additional proxy material) on June 4, 2026, related to a shareholder meeting. The filing supplements previously issued proxy materials, but no specific financial figures, voting results, or material changes were disclosed in the available content. The filing appears to be procedural in nature, with no new substantive proposals or financial data provided.

• · The filing is a DEFA14A (additional proxy soliciting materials) filed under the Securities Exchange Act of 1934.
• · The company was formerly named DREYFUS STRATEGIC MUNICIPALS, INC. and changed its name on October 30, 2018.
• · No financial results, voting outcomes, or new business proposals are included in the supplied portion of the filing.

04-06-2026

Marsh & McLennan Companies, Inc. entered into a $4.25 billion amended and restated five-year credit agreement dated June 2, 2026, replacing its prior $3.5 billion credit agreement from October 2023. The facility is available to the company, Calm Treasury Holdings Limited, MMC Securities LLC, and designated subsidiaries, with Citibank as administrative agent and a syndicate of major banks as joint lead arrangers. The agreement includes customary representations, covenants, events of default, and a guaranty from the company, reflecting an increase in total commitments of $750 million (21.4%) from the prior facility.

• · The agreement is dated June 2, 2026, and was filed as an 8-K on June 4, 2026.
• · Borrowers include the company, Calm Treasury Holdings Limited (formerly MMC Treasury Holdings (UK) Limited), MMC Securities LLC, and any designated subsidiaries.
• · The facility is a five-year revolving credit agreement with a termination date extending the maturity from the prior agreement.
• · The agreement includes a guaranty from Marsh & McLennan Companies, Inc. for obligations of its subsidiaries.
• · The syndication agents include Bank of America, Deutsche Bank, HSBC, JPMorgan Chase, and Wells Fargo.
• · Documentation agents include Barclays, Morgan Stanley, MUFG, PNC, Toronto-Dominion, Bank of Nova Scotia, and Royal Bank of Canada.
• · The agreement contains standard financial covenants, negative pledge, and events of default provisions.
• · The facility can be used for general corporate purposes and includes provisions for letters of credit.

04-06-2026

Parabilis Medicines, Inc. filed an S-1/A registration statement for an IPO of 25,000,000 shares of common stock at an assumed price of $18.00 per share, with an overallotment option for underwriters to purchase up to 3,750,000 additional shares. The company expects net proceeds of approximately $413.6 million from the offering (or $476.4 million if the overallotment is exercised in full), plus an additional $75.0 million from a concurrent private placement with Regeneron. Proceeds will fund clinical development of zolucatetide in desmoid tumors and other indications, pipeline programs, and the Helicon platform. However, the company is not yet profitable, with net losses increasing from $117.9 million in 2024 to $145.9 million in 2025, and a net loss of $45.3 million in Q1 2026 compared to $38.3 million in Q1 2025, reflecting rising R&D and G&A expenses.

• · The company has an accumulated deficit of $586.8 million as of March 31, 2026.
• · Pro forma net loss per share (basic and diluted) for the year ended December 31, 2025 was $(1.81), and for Q1 2026 was $(0.56).
• · Interest income decreased 47.2% from $6.4M in 2024 to $3.4M in 2025, but increased 93.2% from $1.3M in Q1 2025 to $2.4M in Q1 2026.
• · The company's working capital (pro forma as adjusted) is estimated at $776.3 million after the IPO and private placement.
• · The concurrent private placement with Regeneron is at 90% of the IPO price, representing a discount to public investors.
• · The company effected a 1-for-1.5389 reverse stock split on June 3, 2026.
• · The proposed Nasdaq trading symbol is 'PBLS'.

04-06-2026

Pulmatrix, Inc. filed an S-3 registration statement to register up to 490,910 shares of common stock (including 36,364 dividend shares) for resale by a selling stockholder, which are issuable upon conversion of Series B Convertible Preferred Stock. The company will not receive any proceeds from this offering, and existing stockholders face approximately 13% dilution from the maximum issuance. The filing highlights ongoing risks related to stock price depression and shareholder dilution, with no new positive business developments reported.

• · Common stock listed on Nasdaq Capital Market under symbol 'PULM'.
• · Selling stockholder has no recent material relationship with Pulmatrix other than the Preferred Stock ownership per periodic SEC reports.
• · Voting agreement restricts the selling stockholder from transferring shares for a defined period.
• · Registration of conversion shares required within 60 days following the closing date of the Purchase Agreement.
• · Company may incur substantial costs for future capital financing, including investment banking, legal, and accounting fees.

04-06-2026

Somnigroup International Inc. announced that the required 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed merger with Leggett & Platt expired on June 3, 2026, clearing one key regulatory hurdle. The transaction, valued at an undisclosed amount, is expected to close by year-end 2026, but remains subject to several conditions including shareholder approval of Leggett & Platt, additional regulatory clearances in Canada, the EU, the UK, South Korea, and Austria, and the effectiveness of a Form S-4 registration statement. No financial figures or performance metrics were disclosed in this filing.

• · The HSR Act waiting period expired on June 3, 2026, at 11:59 p.m. Eastern Time.
• · Remaining conditions include shareholder approval of Leggett & Platt, clearances under competition laws in Canada, the European Union, the United Kingdom, and the Republic of Korea, and foreign investment approval in Austria.
• · A registration statement on Form S-4 must be filed with the SEC and become effective, with no stop order issued.
• · The merger agreement was originally entered into on April 13, 2026.
• · The transaction is subject to the absence of any material adverse effect on either company since the date of the merger agreement.

04-06-2026

Cushman & Wakefield Ltd. disclosed two key financing events: (1) an amendment to its credit agreement to refinance approximately $848 million of term loans, extending maturity to 2033, raising an additional ~$353 million, and resetting pricing to SOFR+2.25%; and (2) a conditional partial redemption of $350 million of its $550 million outstanding 6.750% Senior Secured Notes due 2028, with a June 15, 2026 redemption date, subject to completion of one or more refinancings. While the amendment improves debt terms and adds liquidity, the redemption is contingent on future transactions, introducing execution risk.

• · The partial redemption of $350M of 2028 Notes is conditional upon the borrower completing one or more refinancings yielding net proceeds sufficient to pay the redemption price and other refinanced debt.
• · The remaining ~$840M of 2025-3 Term Loans are not affected by the amendment and retain their existing pricing and maturity.
• · The redemption price for the 2028 Notes is set at 100% of principal plus accrued and unpaid interest up to the redemption date.

04-06-2026

Leggett & Platt, Incorporated announced that the required 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on June 3, 2026, for its pending merger with Somnigroup International Inc. The transaction, which was previously disclosed on April 13, 2026, is expected to close by year-end 2026, subject to shareholder approval, certain foreign competition and investment clearances, and other customary conditions. No financial figures or period-over-period comparisons are provided in this filing.

• · The Merger Agreement was entered into on April 13, 2026.
• · The HSR Act waiting period expired at 11:59 p.m. Eastern Time on June 3, 2026.
• · Remaining conditions include shareholder approval, clearances under competition laws in Canada, the European Union, the United Kingdom, and the Republic of Korea, and foreign investment approval in Austria.
• · A registration statement on Form S-4 must be filed by Parent and become effective, with no stop order pending.
• · The transaction is subject to the absence of any material adverse effect on either party since the Merger Agreement date.

04-06-2026

At Loar Holdings Inc.'s 2026 Annual Meeting held June 2, shareholders re-elected Raja Bobbili, Alison Bomberg, and Margaret (Peg) McGetrick as directors, ratified Ernst & Young LLP as independent auditor for fiscal 2026, approved on an advisory basis the 2025 named executive officer compensation, and voted to hold future advisory 'say-on-pay' votes annually. All proposals passed with substantial shareholder support; no matters were opposed or declined.

• · Raja Bobbili received 71,125,296 votes for and 994,780 withheld, with 4,062,159 broker non-votes.
• · Alison Bomberg received 64,582,644 votes for and 7,537,432 withheld, the highest withhold count among directors.
• · Margaret (Peg) McGetrick received 71,612,205 votes for and 507,871 withheld.
• · Ratification of Ernst & Young: 76,125,490 for, 54,974 against, 1,771 abstain, zero broker non-votes.
• · Advisory vote on executive compensation: 68,741,460 for, 3,375,301 against, 3,315 abstain, 4,062,159 broker non-votes.
• · Future 'say-on-pay' frequency: 71,950,589 voted for 1 year, 42,262 for 2 years, 125,158 for 3 years, 2,067 abstain.
• · No other matters were brought before shareholders for a vote.
• · The meeting was held on June 2, 2026, and the 8-K was filed on June 4, 2026.

04-06-2026

Avery Dennison announced the appointment of Danny Allouche as President of its Materials Group. Allouche, previously SVP and Chief Strategy and Corporate Development Officer (and interim CFO in late 2024), brings 16 years of internal experience across strategy, M&A, and treasury. The appointment reflects an internal succession but does not disclose separate financial metrics for the Materials Group vs the broader company.

• · Danny Allouche served as interim CFO for a brief period beginning in late 2024.
• · Allouche holds an MBA from UCLA Anderson School of Management and a bachelor’s in economics from Northwestern University.
• · Avery Dennison employs approximately 35,000 employees in more than 50 countries.
• · Reported sales in 2025 were $8.9B.

04-06-2026

Columbus McKinnon reported fiscal year 2026 net sales growth of 24% to $1.19B and record orders of $1.2B (+20%), driven by the transformational Kito Crosby Acquisition. However, the company posted a GAAP net loss of $229.5M for the year (including a $200M goodwill impairment) and a net loss of $238.1M in Q4 FY26. The company issued FY27 guidance of net sales $2.05B-$2.12B, Adj. EBITDA $390M-$410M, and Adj. EPS $1.70-$1.90, with a mixed sentiment reflecting strong revenue growth but significant GAAP losses and leverage of 5.1x.

• · Backlog at Q4 FY26 end was $519.6M: Legacy CMCO $319.7M and Kito Crosby $199.9M.
• · Q4 FY26 U.S. sales were $234.3M (54% of total), non-U.S. sales $203.5M (46% of total).
• · Q4 FY26 gross profit was $102.9M (23.5% margin), down 880 bps YoY; adjusted gross profit $143.1M (32.7% margin), down 250 bps YoY.
• · Full year FY26 net cash used in operating activities was $146.2M; capex $17.9M; free cash flow was a use of $164.1M.
• · Free cash flow excluding deal costs was $68.0M (up 171% YoY on comparable basis).
• · Credit Agreement Net Leverage Ratio at fiscal year-end was 5.1x.
• · Total liquidity: $96.6M cash + $458.9M revolver availability + $5.7M AR facility = $561.2M.
• · FY27 guidance assumptions: interest expense $185M-$190M, amortization $135M-$140M, depreciation $75M-$80M, effective tax rate 25%, 52M adjusted diluted shares outstanding.
• · GAAP diluted loss per share FY26 was $7.40 (vs $0.18 loss in FY25).

04-06-2026

Trulieve Cannabis Corp. completed a deconsolidation transaction on June 3, 2026, spinning off its mixed-use cannabis business (Harvest Enterprises, LLC) to segregate it from its medical cannabis business, aiming to list its subordinate voting shares on the NYSE. The pro forma impact shows a significant reduction in total assets from $2.78B to $2.10B, and a dramatic swing in net income attributable to common shareholders from a reported net income of $2.4M for Q1 2026 to a pro forma net income of $6.0M, but for the full year 2025, the pro forma net loss widened from $116.4M to $802.6M largely due to a one-time $688.7M pre-tax loss on deconsolidation. The retained investment in Harvest is valued at $188.5M under the equity method.

• · Pro forma gross profit was $137.9M for Q1 2026 compared to $170.1M as reported, and $582.1M for FY 2025 compared to $711.2M as reported.
• · Pro forma income from operations was $30.2M for Q1 2026, down from $35.7M as reported.
• · The retained investment in Harvest is classified as equity method investment, not consolidated, and the Non-Voting Units cannot be converted into Common Units until NYSE permits listing of companies that consolidate financials of cannabis businesses with non-medical US operations (Stock Exchange Permissibility Date).
• · Pro forma cash and cash equivalents decreased from $352.9M to $317.6M post-deconsolidation, reflecting the removal of $50.1M in Harvest cash plus $14.8M received in consideration less $3.0M in transaction costs.
• · Pro forma total liabilities decreased by $372.8M, from $1.633B to $1.260B, reflecting removal of Harvest's debt and deferred tax liabilities.
• · The net loss from discontinued operations was eliminated in the pro forma statements, as Harvest is no longer consolidated.

04-06-2026

Fractyl Health announced positive one-year results from its REVEAL-1 Cohort, showing that patients who underwent a single Revita procedure maintained approximately 78% of prior GLP-1-induced weight loss at one year, with 33% continuing to lose weight. The data also showed minimal HbA1c change (0.08%) compared to the ~0.4% increase typically seen after GLP-1 withdrawal, and no procedure-related serious adverse events were reported.

• · Participants lost ~24% total body weight (>50 lbs.) on GLP-1 drugs prior to enrollment, with duration on GLP-1 therapy ranging from five months to five years.
• · 17 of 22 participants had greater than 17.5% total body weight loss on GLP-1 drugs.
• · No procedure-related serious adverse events and no new treatment emergent adverse events were observed.
• · Mild treatment-emergent adverse events occurred in eight of 22 participants (36%), were transient, self-limited, and all occurred within the first month of treatment.
• · No late device-related adverse events were observed.

04-06-2026

Ciena reported strong fiscal Q2 2026 results with revenue of $1.57B, up 39.5% YoY, and adjusted EPS of $1.64, a 290% increase YoY. The company raised its fiscal year 2026 revenue guidance to $6.3B (+32% YoY at midpoint) and provided Q3 guidance of $1.625B. However, the Blue Planet Automation Software and Services segment declined 16.4% YoY to $23.4M, and the company's DSOs increased to 71 days, indicating potential collection challenges.

• · Two customers represented 34.0% of total revenue in Q2 2026.
• · DSOs increased to 71 days from a prior period (not specified), indicating slower cash collection.
• · Inventory turns were 3.6.
• · GAAP operating expense increased 8.0% YoY to $453.7M, while non-GAAP operating expense increased 7.7% to $397.8M.
• · The company repurchased approximately 0.2 million shares for $83.1M under its $1B share repurchase program.
• · Fiscal year 2026 revenue guidance raised to $6.3B ± $100M (32% YoY growth at midpoint).
• · Fiscal Q3 2026 revenue guidance: $1.625B ± $50M.
• · Adjusted gross margin guidance for Q3 2026: 45% ± 50 bps; for FY2026: 44.5% to 45%.
• · Adjusted operating margin guidance for Q3 2026: 19% to 20%; for FY2026: 19% ± 50 bps.

04-06-2026

Pyxus International reported strong Q4 FY2026 results with net sales up 35.2% YoY to $678.2M and operating income surging to $43.7M from $13.7M. Full-year adjusted EBITDA reached a record $226.7M and the leverage ratio improved to 3.52x. However, full-year sales declined 2.8% to $2,413.0M due to a 3.8% drop in average price per kilo and lower value-added tobacco product volumes, and the company guided FY2027 adjusted EBITDA of $210M-$240M, below the record $226.7M achieved in FY2026.

• · Q4 FY2026 operating income was $43.7M vs $13.7M in Q4 FY2025, a 218.9% increase.
• · Full-year FY2026 net income was $14.6M, compared to a net loss of $4.6M in Q4 FY2025 (note: full-year net income not provided for prior year).
• · Cash and cash equivalents increased by $56.1M year-over-year at March 31, 2026.
• · No outstanding borrowings on the $150.0M ABL facility at fiscal year end.
• · Uncommitted inventory was $45.2M, approximately 9% of total processed inventory, consistent with oversupply.
• · FY2027 guidance: sales between $2.3B and $2.5B; adjusted EBITDA between $210M and $240M (below FY2026 record of $226.7M).
• · Interest expense net was $30.1M in Q4 FY2026 vs $26.1M in Q4 FY2025, an increase of 15.3%.
• · Restructuring and asset impairment charges were $1.2M in Q4 FY2026 vs $1.8M in Q4 FY2025.
• · Income from unconsolidated affiliates was $5.7M in Q4 FY2026 vs $0.7M in Q4 FY2025.